Literature DB >> 30887048

Ten years of experience in lung cancer screening in Gdańsk, Poland: a comparative study of the evaluation and surgical treatment of 14 200 participants of 2 lung cancer screening programmes†.

Marcin Ostrowski1, Tomasz Marjański1, Robert Dziedzic1, Małgorzata Jelitto-Górska2, Katarzyna Dziadziuszko2, Edyta Szurowska2, Rafał Dziadziuszko3, Witold Rzyman1.   

Abstract

OBJECTIVES: The European Society of Thoracic Surgeons' recommendations confirm the implementation of lung cancer screening in Europe. We compared 2 screening programmes, the Pilot Pomeranian Lung Cancer Screening Programme (pilot study) and the Moltest Bis programme, completed in a single centre.
METHODS: A total of 8649 healthy volunteers (aged 50-75 years, smoking history ≥20 pack-years) were enrolled in a pilot study between 2009 and 2011, and a total of 5534 healthy volunteers (aged 50-79, smoking history ≥30 pack-years) were enrolled in the Moltest Bis programme between 2016 and 2017. Each participant had a low-dose computed tomography scan of the chest. Participants with a nodule diameter of >10 mm or with suspected tumour morphology underwent a diagnostic work-up in the pilot study. In the Moltest Bis programme, the criteria were based on the volume of the detected nodule on the baseline low-dose computed tomography scan and the volume doubling time in the subsequent rounds.
RESULTS: Lung cancer was diagnosed in 107 (1.24%) and 105 (1.90%) participants of the pilot study and of the Moltest Bis programme, respectively (P = 0.002). A total of 300 (3.5%) and 199 (3.6%) patients, respectively, were referred for further invasive diagnostic work-ups (P = 0.69). A total of 125 (1.5%) and 80 (1.5%) patients, respectively, underwent surgical resection (P = 0.74). The number of resected benign lesions was similar: 44 (35.0%) and 20 (25.0%), respectively (P = 0.13), but with a downwards trend. Lobectomies and/or segmentectomies were performed in 84.0% and 90.0% of patients with lung cancer, respectively (P = 0.22). Notably, patients in the Moltest Bis programme underwent video-assisted thoracoscopic surgery more often than did those in the pilot study (72.5% vs 24.0%, P < 0.001). Surgical patients with stages I and II non-small-cell lung cancer (NSCLC) accounted for 83.4% of the Moltest patients and 86.4% of the pilot study patients (P = 0.44).
CONCLUSIONS: Modified inclusion criteria in the screening programme lead to a higher detection rate of NSCLC. Growing expertise in lung cancer screening leads to increased indications for minimally invasive surgery and an increased proportion of lung-sparing resections. A single-team experience in lung cancer screening does not lead to a major reduction in the rate of diagnostic procedures and operations for non-malignant lesions.
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Low-dose computed tomography; Lung cancer; Screening

Year:  2019        PMID: 30887048     DOI: 10.1093/icvts/ivz079

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  3 in total

1.  Prevalence, symptom burden and under-diagnosis of chronic obstructive pulmonary disease in Polish lung cancer screening population: a cohort observational study.

Authors:  Aleksandra Undrunas; Piotr Kasprzyk; Aleksandra Rajca; Krzysztof Kuziemski; Witold Rzyman; Tomasz Zdrojewski
Journal:  BMJ Open       Date:  2022-04-11       Impact factor: 2.692

2.  Performance of various risk prediction models in a large lung cancer screening cohort in Gdańsk, Poland-a comparative study.

Authors:  Marcin Ostrowski; Franciszek Bińczyk; Tomasz Marjański; Robert Dziedzic; Sylwia Pisiak; Sylwia Małgorzewicz; Mariusz Adamek; Joanna Polańska; Witold Rzyman
Journal:  Transl Lung Cancer Res       Date:  2021-02

3.  Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.

Authors:  Peter J Mazzone; Gerard A Silvestri; Lesley H Souter; Tanner J Caverly; Jeffrey P Kanne; Hormuzd A Katki; Renda Soylemez Wiener; Frank C Detterbeck
Journal:  Chest       Date:  2021-07-13       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.